Risks of obtaining prescription medicines and unapproved injectable peptides through unauthorised channels

Consumers who have been buying prescription medicines and unapproved injectable peptides for weight loss or other health purposes from unauthorised sources should stop this practice immediately. Doing so exposes you to serious risk and harm. These unauthorised sources could include overseas sellers, online platforms or even well-meaning friends and family.

The Health Sciences Authority (HSA) has been receiving reports of serious adverse effects such as anaphylaxis (a potentially life-threatening allergic reaction) and severe vomiting requiring hospitalisation, arising from such purchases and urges the public to exercise caution.

Prescription medicines marketed for weight management

GLP-1 (glucagon-like peptide-1) receptor agonists (or commonly known as GLP-1 medicines) such as semaglutide, liraglutide and tirzepatide have been increasingly touted as quick fixes for weight loss, especially on social media platforms.

GLP-1 medicines are prescription-only medicines approved to treat type-2 diabetes and/or weight management in obese or overweight individuals with weight-related health problems. They should only be used under the medical supervision of a doctor who will assess whether it is appropriate and prescribe the correct dosage.

When used without medical supervision, these medicines can cause serious harm. Adverse effects associated with these medicines include low blood sugar, liver diseases, eye disorders potentially leading to blindness and inflammation of organs such as the pancreas.

HSA has received reports of individuals who experienced adverse effects such as hospitalisation resulting from severe vomiting after consuming GLP-1 medicines obtained overseas or online without a prescription and medical supervision.

Unapproved injectable peptides or other experimental substances marketed for weight loss or other health purposes